The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model

Clinical Microbiology and Infection

Volumn 5, Issue 1, 1999, Pages 12-15

  O'Brien, Matthew ^a   Quach, Thuy ^b   Gilbert, Deborah ^b   Dudley, Michael N ^c   Zinner, Stephen H ^a,b,d,e  

^a BROWN UNIVERSITY   (United States)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

^e NONE   (United States)

Author keywords

Ciprofloxacin; In vitro model; Streptococcus pneumoniae; Trovafloxacin

Indexed keywords

CIPROFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SIMULATION; STREPTOCOCCUS PNEUMONIAE;

EID: 0032901457     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00092.x     Document Type: Article

References (6)

1. Applebaum PC. Emerging resistance to antimicrobial agents in gram-positive bacteria. Drugs 1996; 51(suppl 1): 1-5.
2. Thomson KS, Chartrand SA, Sanders CC, Block SL. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41: 478-80.
3. Morrissey I. Bactericidal activity of trovafloxacin (CP-99,219). J Antimicrob Chemother 1996; 38: 1061-6.
4. Teng R, Harris SC, Nix DE, Schentag JJ, Foulds G, Liston TE. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 1995; 36: 385-94.
5. Blaser J, Stone BB, Zinner SH. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother 1985; 15(suppl. A): 131-7.
6. Barry AL. Procedure for testing antimicrobial agents in agar media: theoretical considerations. In Lorian V, ed. Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins, 1986: 1-26.